Back to Search
Start Over
Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?
- Source :
- Journal of Thoracic Oncology. 7:542-551
- Publication Year :
- 2012
- Publisher :
- Elsevier BV, 2012.
-
Abstract
- Introduction: To evaluate the influence of pretreatment pulmonary function (PF) on survival, early and late pulmonary toxicity after stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer. Methods: Four hundred eighty-three patients with 505 tumors of early-stage non-small cell lung cancer cT1‐3 cN0 were treated with image-guided SBRT at five international institutions (1998‐2010). Sixty-four percent of the tumors were biopsy-proven and 18Ffluorodeoxyglucose-positron emission tomography was performed for staging in 84%. Image-guided SBRT was performed with a median of three fractions to a median total dose of 54 Gy. Pretreatment PF was available for 423 patients, and 617 posttreatment PF tests from 270 patients were available. Results: A large variability of pretreatment PF was observed: the 90% range of forced expiratory volume in 1 second and diffusing capacity for carbon monoxide was 29 to 109% and 5.5 to 19.1 ml/min/mmHg, respectively. PF was significantly correlated with overall survival but not cause-specific survival: diffusing capacity for carbon monoxide of 11.2 ml/min/mmHg differentiated between 3-year overall survival of 66% and 42%. Radiation-induced pneumonitis grade II occurred in 7% of patients and was not increased in patients with lower PF. A significant and progressive change of PF was observed after SBRT: PF decreased by 3.6% and 6.8% on average within 6 and 6 to 24 months after SBRT, respectively. Changes of PF after SBRT were significantly correlated with pretreatment PF: PF improved for worst pretreatment PF and the largest loss was observed for best pretreatment PF. Conclusions: Image-guided SBRT is safe in terms of acute and chronic pulmonary toxicity even for patients with severe pulmonary comorbidities. SBRT should be considered as a curative treatment option for inoperable patients with pretreatment PF as reported in this study.
- Subjects :
- Adult
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Pulmonary function
Lung Neoplasms
Stereotactic body radiotherapy
Pulmonary toxicity
medicine.medical_treatment
Urology
Adenocarcinoma
Radiosurgery
Pulmonary function testing
Non-small cell lung cancer
Carcinoma, Non-Small-Cell Lung
Forced Expiratory Volume
Diffusing capacity
Carcinoma
medicine
Humans
Lung cancer
Survival rate
Aged
Neoplasm Staging
Pneumonitis
Aged, 80 and over
business.industry
International Agencies
Middle Aged
medicine.disease
Respiratory Function Tests
Surgery
Radiation Pneumonitis
Survival Rate
Treatment Outcome
Oncology
Carcinoma, Squamous Cell
Carcinoma, Large Cell
Female
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 15560864
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Journal of Thoracic Oncology
- Accession number :
- edsair.doi.dedup.....ec71132aae67ab2dbc8c717cad7757d9